SCHEMBL1638499

SCHEMBL1638499

Cc1csc(C(=O)NN=C(CC(=O)c2cccs2)C(F)(F)F)c1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.66
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
LMNA P02545 3/20 0.66
HTT P42858 3/20 0.66
GAA P10253 2/20 0.66
CRHBP P24387 1/20 0.66
CRHR2 Q13324 1/20 0.66
ALDH1A1 P00352 5/20 0.61
KDM4E B2RXH2 2/20 0.61
CA9 Q16790 1/20 0.45
RAB9A P51151 6/20 0.40
NPC1 O15118 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
HPGD P15428 1/20 0.39
CTNNB1 P35222 1/20 0.38
WNT3A P56704 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638496 1.00 MAPT (0.66) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1639136 0.80 MAPT (0.59) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1639137 0.80 MAPT (0.59) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1639131 0.79 MAPT (1.00) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1639132 0.79 MAPT (1.00) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1638672 0.79 MAPT (0.66) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1638673 0.79 MAPT (0.66) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1638464 0.79 MAPT (0.70) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1638465 0.79 MAPT (0.70) MAPTMEN1KMT2ALMNAHTT
SCHEMBL13971504 0.78 MAPT (0.82) MAPTMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MAPT 85/4885MEN1 2974/4885KMT2A 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.